Syndax’s Revuforj beats Kura in NPM1-mutated AML.

As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?

But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.

The group is expanding its mRNA-4359 trial to include first-line melanoma.

FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.

The group scraps cobolimab, alongside MAbs against PVRIG and CD96.